Published on 12 Oct 2021 on Benzinga
Ocugen Inc (NASDAQ: OCGN) is trading higher Tuesday after the Indian government approved Bharat Biotech's COVID-19 vaccine, Covaxin, for children between the age of two and 18. Ocugen is a partner of Bharat Biotech.
Bharat Biotech completed Phase 2 and Phase 3 trials of Covaxin on children below 18 years of age in September. The company submitted the trial data to India regulators at the beginning of the month.